A Risk and Benefit Assessment of Treatment for AIDS-Related Kaposi??s Sarcoma
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 20 (5) , 403-425
- https://doi.org/10.2165/00002018-199920050-00002
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Polyethylene Glycol-Liposomal DoxorubicinDrugs, 1997
- Kaposi's sarcoma: Advances and perspectivesJournal of the American Academy of Dermatology, 1996
- Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcomaCancer, 1996
- A Phase II Study of Recombinant Human Interferon-α2a and Zidovudine in Patients with AIDS-Related Kaposi's SarcomaJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Sex hormones as a cofactor in the pathogenesis of epidemic Kaposiʼs sarcomaAIDS, 1995
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994
- PaclitaxelDrugs, 1994
- Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte—macrophage colony-stimulating factor in the treatment of AIDS-related Kaposiʼs sarcomaAIDS, 1992
- Clinical aspects of Kaposiʼs sarcomaCurrent Opinion in Oncology, 1992
- Phase II study of teniposide in patients with AIDS-related Kaposi's sarcomaEuropean Journal of Cancer and Clinical Oncology, 1991